|Systematic (IUPAC) name|
|Trade names||Advil, Brufen, Motrin, Nurofen, and others|
|Licence data||US FDA:|
|Pregnancy cat.||C (AU) D (US)|
|Legal status||Unscheduled (AU) OTC (CA) GSL (UK) RX/OTC (US)|
|Routes||Oral, rectal, topical, and intravenous|
|ATC code||C01 G02 M01 M02|
|PDB ligand ID||IBP (, )|
|Mol. mass||206.29 g/mol|
|Density||1.03 gr/ml g/cm³|
|Melt. point||76 °C (169 °F)|
|(what is this?)|
Ibuprofen (INN) (// or // EYE-bew-PROH-fən; from iso-butyl-propanoic-phenolic acid) is a nonsteroidal anti-inflammatory drug (NSAID) used for relieving pain, alleviating fever, and reducing inflammation.
Ibuprofen has an antiplatelet effect, though it is relatively mild and somewhat short-lived compared with aspirin or prescription antiplatelet drugs. In general, ibuprofen also has a vasodilation effect. Ibuprofen is a 'core' medicine in the World Health Organization's Model List of Essential Medicines necessary to meet the minimum medical needs of a basic healthcare system.
Ibuprofen was derived from propanoic acid by the research arm of Boots Company during the 1960s and patented in 1961. Originally marketed as Brufen, ibuprofen is available under a variety of popular trademarks, including Motrin, Nurofen, Advil, Nuprin and many others. Generic formulations are available as well.
- 1 Medical uses
- 2 Adverse effects
- 3 Mechanism of action
- 4 Chemistry
- 5 History
- 6 Availability
- 7 Research
- 8 References
- 9 External links
Ibuprofen is used primarily for fever, pain, dysmenorrhea and inflammatory diseases such as osteoarthritis and rheumatoid arthritis. It is also used for pericarditis and patent ductus arteriosus.
Ibuprofen has a dose-dependent duration of action of around four to eight hours, which is longer than suggested by its short half-life. Onset of analgesia (time to effect) is 24.5 minutes using liquigel format orally. The recommended dose varies with body mass and indication. A dose of 200 mg per dose and 1200 mg per day is considered the maximum amount for over-the-counter use, and a dose of 800 mg per dose and 3200 mg per day is considered the maximum amount for prescription use under a doctor's supervision. Unlike aspirin, which breaks down in solution, ibuprofen is stable, thus it can be available in topical gel form, which is absorbed through the skin, and can be used for sports injuries, with less risk of digestive problems.
In Europe, Australia, and New Zealand, ibuprofen lysine (the lysine salt of ibuprofen, sometimes called "ibuprofen lysinate" even though the lysine is in cationic form) is licensed for treatment of the same conditions as ibuprofen. The lysine salt increases water solubility, allowing intravenous use, and is indicated for closure of a patent ductus arteriosus in premature infants weighing between 500 and 1,500 grams (1 and 3 lb), who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective.
With regard to this indication, ibuprofen lysine is an effective alternative to intravenous indomethacin, and may be advantageous in terms of kidney function. Ibuprofen lysine has been shown to have a more rapid onset of action compared to acid ibuprofen.
In UK Ibuprofen Lysine is marketed as express pain relief, tension headache relief and more commonly migraine relief medicine. Usually available in packing of 16 342 mg tablets the pack is marketed OTC by most superstores and pharmacies as their own branded product including, but not limited to, Asda, Tesco and Superdrug.
Common adverse effects include: nausea, dyspepsia, gastrointestinal ulceration/bleeding, raised liver enzymes, diarrhea, constipation, epistaxis, headache, dizziness, rash, salt and fluid retention, and hypertension. A study from 2010 has shown regular use of NSAIDs was associated with an increase in hearing loss.
Ibuprofen appears to have the lowest incidence of digestive adverse drug reactions of all the nonselective NSAIDs. However, this holds true only at lower doses of ibuprofen, so over-the-counter (OTC) preparations of ibuprofen are, in general, labeled to advise a maximum daily dose of 1,200 mg.
Ibuprofen may be quantitated in blood, plasma, or serum to demonstrate the presence of the drug in a person having experienced an anaphylactic reaction, confirm a diagnosis of poisoning in hospitalized patients, or assist in a medicolegal death investigation. A nomogram relating ibuprofen plasma concentration, time since ingestion, and risk of developing renal toxicity in overdose patients has been published.
Along with several other NSAIDs, chronic ibuprofen use has been found correlated with risk of hypertension and myocardial infarction (heart attack), particularly among those chronically using high doses. In older hypertensive patients treated with hydrochlorothiazide, ibuprofen in doses of 1800 mg per day was found to significantly increase systolic blood pressure.
Increased risk of kidney cancer
A 2011 study in the Archives of Internal Medicine reported a 51% increase in the rate of renal cell carcinoma, the most common form of kidney cancer, in nurses who regularly took ibuprofen and other NSAIDs, such as naproxen.
Along with other NSAIDs, ibuprofen has been associated with the onset of bullous pemphigoid or pemphigoid-like blistering. As with other NSAIDs, ibuprofen has been reported to be a photosensitising agent, but it is considered a weak photosensitising agent compared to other members of the 2-arylpropionic acid class. Like other NSAIDs, ibuprofen is an extremely rare cause of the autoimmune disease Stevens-Johnson syndrome (SJS).
Drinking alcohol when taking ibuprofen may increase risk of stomach bleeding.
According to the US Food and Drug Administration, "ibuprofen can interfere with the antiplatelet effect of low-dose aspirin (81 mg per day), potentially rendering aspirin less effective when used for cardioprotection and stroke prevention." Allowing sufficient time between doses of ibuprofen and immediate-release (IR) aspirin can avoid this problem. The recommended elapsed time between a 400-mg dose of ibuprofen and a dose of aspirin depends on which is taken first. It would be 30 minutes or more for ibuprofen taken after IR aspirin, and 8 hours or more for ibuprofen taken before IR aspirin. However, this timing cannot be recommended for enteric-coated aspirin. But, if ibuprofen is taken only occasionally without the recommended timing, the reduction of the cardioprotection and stroke prevention of a daily aspirin regimen is minimal.
Erectile dysfunction risk
A 2005 study linked long-term (over three months) use of NSAIDs, including ibuprofen, with a 140% higher risk of erectile dysfunction. The study, conducted at Kaiser Permanente and published in the Journal of Urology, reported, "regular nonsteroidal anti-inflammatory drug use is associated with erectile dysfunction beyond what would be expected due to age and other conditions". The director of research for Kaiser Permanente added, "There are many proven benefits of nonsteroidals in preventing heart disease and for other conditions. People shouldn't stop taking them based on this observational study. However, if a man is taking this class of drugs and has ED, it's worth a discussion with his doctor".
Ibuprofen overdose has become common since it was licensed for OTC use. Many overdose experiences are reported in the medical literature, although the frequency of life-threatening complications from ibuprofen overdose is low. Human response in cases of overdose ranges from absence of symptoms to fatal outcome despite intensive-care treatment. Most symptoms are an excess of the pharmacological action of ibuprofen, and include abdominal pain, nausea, vomiting, drowsiness, dizziness, headache, tinnitus, and nystagmus. Rarely, more severe symptoms, such as gastrointestinal bleeding, seizures, metabolic acidosis, hyperkalaemia, hypotension, bradycardia, tachycardia, atrial fibrillation, coma, hepatic dysfunction, acute renal failure, cyanosis, respiratory depression, and cardiac arrest have been reported. The severity of symptoms varies with the ingested dose and the time elapsed; however, individual sensitivity also plays an important role. Generally, the symptoms observed with an overdose of ibuprofen are similar to the symptoms caused by overdoses of other NSAIDs.
Correlation between severity of symptoms and measured ibuprofen plasma levels is weak. Toxic effects are unlikely at doses below 100 mg/kg, but can be severe above 400 mg/kg (around 150 tablets of 200 mg units for an average man); however, large doses do not indicate the clinical course is likely to be lethal. A precise lethal dose is difficult to determine, as it may vary with age, weight, and concomitant diseases of the individual patient.
Therapy is largely symptomatic. In cases presenting early, gastric decontamination is recommended. This is achieved using activated charcoal; charcoal adsorbs the drug before it can enter the systemic circulation. Gastric lavage is now rarely used, but can be considered if the amount ingested is potentially life-threatening, and it can be performed within 60 minutes of ingestion. Emesis is not recommended. The majority of ibuprofen ingestions produce only mild effects and the management of overdose is straightforward. Standard measures to maintain normal urine output should be instituted and renal function monitored. Since ibuprofen has acidic properties and is also excreted in the urine, forced alkaline diuresis is theoretically beneficial. However, because ibuprofen is highly protein-bound in the blood, renal excretion of unchanged drug is minimal. Forced alkaline diuresis is, therefore, of limited benefit. Symptomatic therapy for hypotension, gastrointestinal bleeding, acidosis, and renal toxicity may be indicated. On occasion, close monitoring in an intensive-care unit for several days is necessary. A patient who survives the acute intoxication usually experiences no late sequelae.
A Canadian study published in the Canadian Medical Association Journal of thousands of pregnant woman suggests those taking any type or amount of NSAIDs (including ibuprofen, diclofenac and naproxen) were 2.4 times more likely to miscarry than those not taking the drugs. However, an Israeli study following thousands of women found no increased risk of miscarriage in the group of mothers using NSAIDs.
Mechanism of action
Nonsteroidal anti-inflammatory drugs such as ibuprofen work by inhibiting the enzyme cyclooxygenase (COX), which converts arachidonic acid to prostaglandin H2 (PGH2). PGH2, in turn, is converted by other enzymes to several other prostaglandins (which are mediators of pain, inflammation, and fever) and to thromboxane A2 (which stimulates platelet aggregation, leading to the formation of blood clots).
Like aspirin and indomethacin, ibuprofen is a nonselective COX inhibitor, in that it inhibits two isoforms of cyclooxygenase, COX-1 and COX-2. The analgesic, antipyretic, and anti-inflammatory activity of NSAIDs appears to operate mainly through inhibition of COX-2, whereas inhibition of COX-1 would be responsible for unwanted effects on the gastrointestinal tract. However, the role of the individual COX isoforms in the analgesic, anti-inflammatory, and gastric damage effects of NSAIDs is uncertain and different compounds cause different degrees of analgesia and gastric damage.
To achieve the beneficial effects of ibuprofen and other NSAIDs without gastrointestinal ulceration and bleeding, selective COX-2 inhibitors were developed to inhibit the COX-2 isoform without inhibition of COX-1.
Ibuprofen is only very slightly soluble in water. Less than 1 mg of ibuprofen dissolves in 1 ml water (< 1 mg/ml).
Ibuprofen is produced industrially as a racemate. The compound, like other 2-arylpropionate derivatives (including ketoprofen, flurbiprofen, naproxen, etc.), does contain a chiral center in the α-position of the propionate moiety. So two enantiomers of ibuprofen occur, with the potential for different biological effects and metabolism for each enantiomer. Indeed, the (S)-(+)-ibuprofen (dexibuprofen) was found to be the active form both in vitro and in vivo.
It was logical, then, to consider the potential for improving the selectivity and potency of ibuprofen formulations by marketing ibuprofen as a single-enantiomer product (as occurs with naproxen, another NSAID). Further in vivo testing, however, revealed the existence of an isomerase (alpha-methylacyl-CoA racemase), which converted (R)-ibuprofen to the active (S)-enantiomer.
The synthesis of this compound is a popular case study in green chemistry. The original Boots synthesis of ibuprofen consisted of six steps, started with the Friedel-Crafts acetylation of isobutylbenzene. Reaction with ethyl chloroacetate (Darzens reaction) gave the α,β-epoxy ester, which was hydrolyzed and decarboxylated to the aldehyde. Reaction with hydroxylamine gave the oxime, which was converted to the nitrile, then hydrolyzed to the desired acid:
Ibuprofen was derived from propionic acid by the research arm of Boots Group during the 1960s. It was discovered by Andrew RM Dunlop, with colleagues Stewart Adams, John Nicholson, Vonleigh Simmons, Jeff Wilson and Colin Burrows, and patented in 1961. The drug was launched as a treatment for rheumatoid arthritis in the United Kingdom in 1969, and in the United States in 1974. Adams initially tested his drug on a hangover. He was subsequently awarded an OBE in 1987. Boots was awarded the Queen's Award for Technical Achievement for the development of the drug in 1987.
Ibuprofen was made available under prescription in the United Kingdom in 1969, and in the United States in 1974. In the years since, the good tolerability profile, along with extensive experience in the population, as well as in so-called phase IV trials (post-approval studies), has resulted in the availability of ibuprofen over the counter (OTC) in pharmacies worldwide, as well as in supermarkets and other general retailers.
Ibuprofen is commonly available in the United States up to the FDA's 200 mg 1984 dose limit OTC, rarely used higher by prescription.
In Canada, the OTC dose limit is 400 mg, with 600 mg and 800 mg routinely available by prescription.
In 2009, the first injectable formulation of ibuprofen was approved in the United States, under the trade name Caldolor. Ibuprofen was the only parenteral for both pain and fever available in the country prior to the approval of Ofirmev (acetaminophen) injection by the FDA.
Ibuprofen is sometimes used for the treatment of acne, because of its anti-inflammatory properties, and has been sold in Japan in topical form for adult acne. As with other NSAIDs, ibuprofen may be useful in the treatment of severe orthostatic hypotension (low blood pressure when standing up). In some studies, ibuprofen showed superior results compared to a placebo in the prophylaxis of Alzheimer's disease, when given in low doses over a long time. Some of the aforementioned uses would be considered off-label uses in some countries.
Ibuprofen has been associated with a lower risk of Parkinson's disease, and may delay or prevent it. Aspirin, other NSAIDs, and paracetamol (acetaminophen) had no effect on the risk for Parkinson's. In March 2011, researchers at Harvard Medical School announced in Neurology that ibuprofen had a neuroprotective effect against the risk of developing Parkinson's disease. People regularly consuming ibuprofen were reported to have a 38% lower risk of developing Parkinson's disease, but no such effect was found for other pain relievers, such as aspirin and paracetamol. Use of ibuprofen to lower the risk of Parkinson's disease in the general population would not be problem-free, given the possibility of adverse effects on the urinary and digestive systems.
- Van Esch, A.; Van Steensel-Moll, H. A.; Steyerberg, E. W.; Offringa, M.; Habbema, J. D.; Derksen-Lubsen, G. (1995). "Antipyretic efficacy of ibuprofen and acetaminophen in children with febrile seizures". Archives of pediatrics & adolescent medicine 149 (6): 632–637. doi:10.1001/archpedi.1995.02170190042007. PMID 7767417.
- Apstein CS,Vogel MM (January 22, 1982). Coronary arterial vasodilator effect of ibuprofen. PMID 7053413.
- WHO Model List of Essential Medicines (16th ed.). World Health Organization (WHO). March 2009. Retrieved 2011-03-30.
- WHO Model List of Essential Medicines for Children (2nd ed.). World Health Organization (WHO). March 2010. Retrieved 2011-03-30.
- Stuart MC, Kouimtzi M, Hill SR, ed. (2009). WHO Model Formulary 2008 (2nd ed.). World Health Organization (WHO). ISBN 978-92-4-154765-9. Retrieved 2011-03-30.
- WHO Model Formulary for Children 2010 (2nd ed.). World Health Organization (WHO). 2010. ISBN 978-92-4-159932-0. Retrieved 2011-03-30.
- Adams, S. S. (1992). "The propionic acids: A personal perspective". Journal of clinical pharmacology 32 (4): 317–323. doi:10.1002/j.1552-4604.1992.tb03842.x. PMID 1569234.
- "PubMed Health - Ibuprofen". U.S. National Library of Medicine. 2010-10-01. Retrieved 2011-01-20.
- "Ibuprofen". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
- "Topical NSAIDs: plasma and tissue concentrations". Bandolier.
- "Neoprofen (ibuprofen lysine) injection. Package insert". Ovation Pharmaceuticals.
- Su, P. H.; Chen, J. Y.; Su, C. M.; Huang, T. C.; Lee, H. S. (2003). "Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants". Pediatrics international : official journal of the Japan Pediatric Society 45 (6): 665–670. PMID 14651538.
- Geisslinger, G.; Dietzel, K.; Bezler, H.; Nuernberg, B.; Brune, K. (1989). "Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid". International journal of clinical pharmacology, therapy, and toxicology 27 (7): 324–328. PMID 2777420.
- Rossi, S., ed. (2004). Australian Medicines Handbook (2004 ed.). Australian Medicines Handbook. ISBN 0-9578521-4-2. OCLC 224121065.
- Curhan, S. G.; Eavey, R.; Shargorodsky, J.; Curhan, G. C. (2010). "Analgesic Use and the Risk of Hearing Loss in Men". The American Journal of Medicine 123 (3): 231–237. doi:10.1016/j.amjmed.2009.08.006. PMC 2831770. PMID 20193831.
- Ayres, JG, Fleming D, Whittington R. (1987). "Asthma death due to ibuprofen". Lancet.
- "Ibuprofen". U.S. Food and Drug Administration (FDA).
- Baselt, R. (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 758–761.
- Forman, J. P.; Stampfer, M. J.; Curhan, G. C. (2005). "Non-Narcotic Analgesic Dose and Risk of Incident Hypertension in US Women". Hypertension 46 (3): 500–507. doi:10.1161/01.HYP.0000177437.07240.70. PMID 16103274.
- Hippisley-Cox, J.; Coupland, C. (2005). "Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis". BMJ 330 (7504): 1366. doi:10.1136/bmj.330.7504.1366. PMC 558288. PMID 15947398.
- Gurwitz, J. H.; Everitt, D. E.; Monane, M.; Glynn, R. J.; Choodnovskiy, I.; Beaudet, M. P.; Avorn, J. (1996). "The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons". The journals of gerontology. Series A, Biological sciences and medical sciences 51 (2): M74–M79. doi:10.1093/gerona/51A.2.M74. PMID 8612107.
- Cortez, Michelle (September 12, 2011). "Commonly Used Pain Pills Increase Kidney Cancer Risk in Study". Bloomberg.
- Chan, L. S. (2011). "Bullous Pemphigoid". eMedicine Reference. Medscape.
- Bergner, T.; Przybilla, B. (1992). "Photosensitization caused by ibuprofen". Journal of the American Academy of Dermatology 26 (1): 114–116. PMID 1531054.
- Raksha MP, Marfatia YS (2008). "Clinical study of cutaneous drug eruptions in 200 patients". Indian J Dermatol Venereol Leprol 74 (1): 80. doi:10.4103/0378-6323.38431. PMID 18193504.
- Ward, K. E.; Archambault, R.; Mersfelder, T. L. (2010). "Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature". American Journal of Health-System Pharmacy 67 (3): 206–213. doi:10.2146/ajhp080603. PMID 20101062.
- "Ibuprofen". Drugs.com.
- "Information for Healthcare Professionals: Concomitant Use of Ibuprofen and Aspirin". U.S. Food and Drug Administration (FDA). September 2006. Retrieved 2010-11-22.
- Shiri, R.; Koskimäki, J.; Häkkinen, J.; Tammela, T. L. J.; Auvinen, A.; Hakama, M. (2006). "Effect of Nonsteroidal Anti-Inflammatory Drug Use on the Incidence of Erectile Dysfunction". The Journal of Urology 175 (5): 1812–1815; discussion 1815–6. doi:10.1016/S0022-5347(05)01000-1. PMID 16600768.
- "Non-steroidal anti-inflammatory drugs linked to increased risk of erectile dysfunction". sciencedaily.com. 2011-03-02. Retrieved 2011-06-07.
- Mary Brophy Marcus (March 2011). "New study links pain relievers to erectile dysfunction". USA Today.
- McElwee, N. E.; Veltri, J. C.; Bradford, D. C.; Rollins, D. E. (1990). "A prospective, population-based study of acute ibuprofen overdose: Complications are rare and routine serum levels not warranted". Annals of Emergency Medicine 19 (6): 657–662. doi:10.1016/S0196-0644(05)82471-0. PMID 2188537.
- Vale, J. A.; Meredith, T. J. (1986). "Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management". Medical toxicology 1 (1): 12–31. PMID 3537613.
- Volans, G.; Hartley, V.; McCrea, S.; Monaghan, J. (2003). "Non-opioid analgesic poisoning". Clinical medicine (London, England) 3 (2): 119–123. PMID 12737366.
- Seifert, S. A.; Bronstein, A. C.; McGuire, T. (2000). "Massive ibuprofen ingestion with survival". Journal of toxicology. Clinical toxicology 38 (1): 55–57. PMID 10696926.
- "Position paper: Ipecac syrup". Journal of toxicology. Clinical toxicology 42 (2): 133–143. 2004. doi:10.1081/CLT-120037421. PMID 15214617.
- Hall, A. H.; Smolinske, S. C.; Conrad, F. L.; Wruk, K. M.; Kulig, K. W.; Dwelle, T. L.; Rumack, B. H. (1986). "Ibuprofen overdose: 126 cases". Annals of Emergency Medicine 15 (11): 1308–1313. doi:10.1016/S0196-0644(86)80617-5. PMID 3777588.
- "Miscarriage risk doubled: drug study". theage.com.au. 2011-09-07. Retrieved 2011-09-07.
- Sharon Daniel, Gideon Koren, Eitan Lunenfeld, Natalya Bilenko, Ronit Ratzon, Amalia Levy (2014). "Fetal exposure to nonsteroidal anti-inflammatory drugs and spontaneous abortions" Canadian Medical Association Journal
- Rao, P.; Knaus, E. E. (2008). "Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond". Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 11 (2): 81s–110s. PMID 19203472.
- Kakuta, H.; Zheng, X.; Oda, H.; Harada, S.; Sugimoto, Y.; Sasaki, K.; Tai, A. (2008). "Cyclooxygenase-1-Selective Inhibitors Are Attractive Candidates for Analgesics That Do Not Cause Gastric Damage. Design and in Vitro/in Vivo Evaluation of a Benzamide-Type Cyclooxygenase-1 Selective Inhibitor". Journal of Medicinal Chemistry 51 (8): 2400–2411. doi:10.1021/jm701191z. PMID 18363350.
- "Pain Medications". eMedicine. 2006-02-13. Retrieved 2010-06-07.
- Motrin (Ibuprofen) drug description - FDA-approved labeling for prescription drugs and medications at RxList
- Chen, C. S.; Shieh, W. R.; Lu, P. H.; Harriman, S.; Chen, C. Y. (1991). "Metabolic stereoisomeric inversion of ibuprofen in mammals". Biochimica et Biophysica Acta 1078 (3): 411–417. doi:10.1016/0167-4838(91)90164-U. PMID 1859831.
- Tracy, T. S.; Hall, S. D. (1992). "Metabolic inversion of (R)-ibuprofen. Epimerization and hydrolysis of ibuprofenyl-coenzyme A". Drug metabolism and disposition: the biological fate of chemicals 20 (2): 322–327. PMID 1352228.
- Reichel, C.; Brugger, R.; Bang, H.; Geisslinger, G.; Brune, K. (1997). "Molecular cloning and expression of a 2-arylpropionyl-coenzyme a epimerase: A key enzyme in the inversion metabolism of ibuprofen". Molecular Pharmacology 51 (4): 576–582. PMID 9106621.
- "Ibuprofen — a case study in green chemistry" (pdf). Royal Society of Chemistry.
- US patent 3385886, Stuart, N. J. & Sanders, A. S., issued 1968-05-28, assigned to Boots Pure Drug Company
- "Presidential Green Chemistry Challenge: 1997 Greener Synthetic Pathways Award". United States EPA. Retrieved 2009-08-18.
- Kjonaas, R. A.; Williams, P. E.; Counce, D. A.; Crawley, L. R. (2011). "Synthesis of Ibuprofen in the Introductory Organic Laboratory". Journal of Chemical Education 88 (6): 825–828. doi:10.1021/ed100892p.
- Lambert, Victoria (2007-10-08). "Dr. Stewart Adams: 'I tested ibuprofen on my hangover'". The Daily Telegraph (London). Retrieved 2008-01-20.
- "Written submission to the NDAC meeting on risks of NSAIDs presented by the International Ibuprofen Foundation". International Ibuprofen Foundation. August 2002. Retrieved 20 March 2014.
- "Drug Approval Package: Caldolor (Ibuprofen) NDA #022348". U.S. Food and Drug Administration (FDA). March 11, 2010.
- "FDA Approves Injectable Form of Ibuprofen" (Press release). U.S. Food and Drug Administration (FDA). June 11, 2009.
- "FDA Approves Caldolor: Cumberland Pharmaceuticals Announces FDA Approval of Caldolor" (Press release). Drugs.com. June 11, 2009. Retrieved 2009-06-13.
- Wong, R. C.; Kang, S.; Heezen, J. L.; Voorhees, J. J.; Ellis, C. N. (1984). "Oral ibuprofen and tetracycline for the treatment of acne vulgaris". Journal of the American Academy of Dermatology 11 (6): 1076–1081. doi:10.1016/S0190-9622(84)80192-9. PMID 6239884.
- "In Japan, an OTC ibuprofen ointment (Fukidia) for alleviating adult acne has been launched". Inpharma (Adis) 1 (1530): 18. March 25, 2006. ISSN 1173-8324.
- Zawada Jr, E. T. (1982). "Renal consequences of nonsteroidal antiinflammatory drugs". Postgraduate Medicine 71 (5): 223–230. PMID 7041104.
- Townsend, K. P.; Praticò, D. (2005). "Novel therapeutic opportunities for Alzheimer's disease: Focus on nonsteroidal anti-inflammatory drugs". The FASEB Journal 19 (12): 1592–1601. doi:10.1096/fj.04-3620rev. PMID 16195368.
- Vlad, S. C.; Miller, D. R.; Kowall, N. W.; Felson, D. T. (2008). "Protective effects of NSAIDs on the development of Alzheimer disease". Neurology 70 (19): 1672–1677. doi:10.1212/01.wnl.0000311269.57716.63. PMC 2758242. PMID 18458226.
- Chen, H.; Jacobs, E.; Schwarzschild, M. A.; McCullough, M. L.; Calle, E. E.; Thun, M. J.; Ascherio, A. (2005). "Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease". Annals of Neurology 58 (6): 963–967. doi:10.1002/ana.20682. PMID 16240369.
- Gao, X.; Chen, H.; Schwarzschild, M. A.; Ascherio, A. (2011). "Use of ibuprofen and risk of Parkinson disease". Neurology 76 (10): 863–869. doi:10.1212/WNL.0b013e31820f2d79. PMC 3059148. PMID 21368281.
- McSharry, C. (2011). "Parkinson disease: Could over-the-counter treatment protect against Parkinson disease?". Nature Reviews Neurology 7 (5): 244. doi:10.1038/nrneurol.2011.49. PMID 21555992.
- Bower, J. H.; Ritz, B. (2011). "Is the answer for Parkinson disease already in the medicine cabinet?: Unfortunately not". Neurology 76 (10): 854–855. doi:10.1212/WNL.0b013e31820f2e7a. PMID 21368280.
- Mary Brophy Marcus (March 2, 2011). "Ibuprofen may reduce risk of getting Parkinson's disease". USA Today.
|Wikimedia Commons has media related to Ibuprofen.|
- U.S. National Library of Medicine: MedlinePlus Drug Information: Ibuprofen
- University of Bristol chemistry department page on Ibuprofen
- U.S. National Library of Medicine: Drug Information Portal - Ibuprofen
- Caldolor Full Prescribing Information
- Ibuprofen use in the treatment of RSD